Current Report Filing (8-k)
January 10 2022 - 08:31AM
Edgar (US Regulatory)
0000849636 false 0000849636 2022-01-04
2022-01-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported):
January 4, 2022
RESPIRERX PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
|
Delaware |
|
1-16467 |
|
33-0303583 |
|
(State or
other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S
Employer
Identification
No.)
|
|
126 Valley Road,
Suite C
Glen Rock,
New Jersey
|
|
07452 |
|
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
(201)
444-4947
(Former
name or former address, if changed since last
report.)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of
each class |
|
Trading
Symbol(s) |
|
Name of each
exchange on which registered |
| N/A |
|
N/A |
|
N/A |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934
(§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On January
4, 2022, Mr. Timothy Jones, the President and Chief Executive
Officer and member of the Board of Directors (“BOD”) of RespireRx
Pharmaceuticals, Inc. (the “Company”) notified the Company of his
intent to resign which he and the Company subsequently agreed would
target January 31, 2022 and would include his resignation as a
member of the BOD.
The BOD
intends to appoint Arnold S. Lippa as the Interim President and
Interim Chief Executive effective upon Mr. Jones’ departure. The
terms of Mr. Jones’ employment agreement, as amended, remain in
effect.
The Company
has had non-contentious preliminary discussions with Mr. Jones
regarding the timing, transfer of responsibilities, process,
expectations during the transition period through his departure
date, as well as related financial matters. The discussions were
preliminary and do not represent final terms, conditions or
processes at this time. If the Company enters into any subsequent
agreement with Mr. Jones regarding the circumstances of his
resignation or departure, the Company will file a subsequent report
on Form 8-K.
Mr. Jones
indicated in those preliminary discussions that he is resigning to
pursue a consulting practice.
Pursuant to
the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| Date: January 10,
2022 |
RESPIRERX PHARMACEUTICALS
INC.
(Registrant) |
|
|
|
|
| |
By: |
/s/
Jeff Eliot Margols |
| |
|
Jeff
Eliot Margolis
|
| |
|
Senior Vice President,
Chief Financial Officer, Secretary and Treasurer |
RespireRx Pharmaceuticals (QB) (USOTC:RSPI)
Historical Stock Chart
From Apr 2022 to May 2022
RespireRx Pharmaceuticals (QB) (USOTC:RSPI)
Historical Stock Chart
From May 2021 to May 2022
